Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,285 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07070219RecruitingPhase 1/Phase 2
Study of CTD402 for T-cell leukemia or lymphoma
This trial tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to other treatments. It looks at whether adding a donor stem cell transplant after CTD402 can help control the disease.
Palo Alto, CaliforniaAges 12 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07078929RecruitingPhase 1
CAR T-cell therapy for children with relapsed or refractory ALL
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
Bangkok, BangkoknoiAges 1–18 - NCT07092670Recruiting
Melanoma treatment after surgery and its effect on fertility
This study looks at how adjuvant therapy (treatment after surgery) affects fertility in women under 40 who have had their melanoma completely removed. It will help doctors understand and manage the impact on future childbearing.
BariAges Up to 40 years - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT07108309RecruitingPhase 2
Study of BCD-236 with chemotherapy for recurrent triple-negative breast cancer
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
BrestAges 18–74 - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07122076RecruitingEarly Phase 1
GT719 injection for moderate to severe autoimmune diseases
This trial tests if a new cell therapy called GT719 can help people with moderate to severe lupus, inflammatory myopathy, or systemic sclerosis that hasn't gotten better with standard treatments. It aims to find a new option for those who have not responded well to usual medications.
ShanghaiAges 18–65 - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Zaragoza, AragonAges 18 years+ - NCT07129642RecruitingEarly Phase 1
Donor CAR-T cells for hard-to-treat Graves' disease
This trial tests a new type of cell therapy called CAR-T cells made from a donor. The cells target B cells that may drive Graves' disease. It's for people whose Graves' disease has not gotten better with usual treatments.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07132775Recruiting
Full-body electrical stimulation suit for spasticity and pain
This study tests a full-body suit that uses mild electrical stimulation to help reduce spasticity, pain, and overactive reflexes in people with conditions like Multiple Sclerosis or Fibromyalgia. It aims to see if the suit is safe and can improve comfort and movement.
Chicago, IllinoisAges 18–75 - NCT07137624Recruiting
Can thinking about walking help MS patients?
This study tests whether imagining or watching walking movements can improve walking ability in people with multiple sclerosis. It focuses on low-risk, non-invasive mental exercises that may help retrain the brain and muscles.
AnkaraAges 18 years+ - NCT07151534Recruiting
Body awareness, trunk stability, and arm function in MS
This study explores how body awareness and trunk stability relate to arm function in people with multiple sclerosis (MS). It aims to understand these connections to help improve rehabilitation for MS patients.
Ankara, AltındağAges 10 years+ - NCT07159789Recruiting
Brain stimulation to improve leg weakness in MS
This study tests whether a noninvasive brain stimulation technique (rTMS) can help people with multiple sclerosis who have leg stiffness and weakness. You will receive daily sessions over two weeks to see if it improves walking and quality of life.
Gatineau, QuebecAges 18–70 - NCT07183683Recruiting
Acupuncture for bladder problems in women with MS
This study tests whether stimulating acupuncture points on the lower leg can help women with multiple sclerosis who have overactive bladder symptoms like urgency, frequent urination, or leaking. It is for women with relapsing-remitting MS who are not using a catheter regularly.
Berlin, State of BerlinAges 18–60 - NCT07184853Recruiting
Ruxolitinib with etanercept vs ruxolitinib for severe GVHD
This trial tests whether adding etanercept to ruxolitinib works better than ruxolitinib alone for severe graft-versus-host disease (GVHD) that has not responded to steroids. GVHD is a common complication after a stem cell transplant where donor cells attack the patient's body.
Hangzhou, ZhejiangAges 12–70 - NCT07189455RecruitingPhase 3
Comparing ZG006 to chemotherapy for relapsed small cell lung cancer
This study compares a new drug called ZG006 against standard chemotherapy for people with small cell lung cancer that has come back after prior treatment. The goal is to see if ZG006 works better or has fewer side effects.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07197580RecruitingPhase 3
Study of a targeted radiation therapy for advanced kidney cancer
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Sydney, New South WalesAges 18 years+ - NCT07225868Recruiting
Coaching to boost cognitive rehab in MS
This trial tests if coaching in goal-directed behavior can improve cognitive rehabilitation for people with relapsing-remitting or secondary progressive MS. It aims to help patients better manage daily tasks and thinking challenges.
Buffalo, New YorkAges 18–65 - NCT07227818RecruitingPhase 3
Testing NBI-1117568 to prevent schizophrenia relapse
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
Garden Grove, CaliforniaAges 18–65 - NCT07242963Recruiting
Study of Shh medulloblastoma with U1 mutation
This study looks at people with a certain type of brain tumor called sonic hedgehog medulloblastoma that has come back or not responded to treatment. Researchers want to learn more about these tumors that have a specific genetic change (U1 mutation), which may help find better treatments in the future.
Houston, TexasAges 3–50 - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT07024706RecruitingPhase 2
Study of acalabrutinib plus venetoclax for relapsed CLL
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
Boston, MassachusettsAges 18–130 - NCT07254754RecruitingPhase 2
CAR-T cell therapy for late-relapse aggressive lymphoma
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
A Coruña, A CoruñaAges 18 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,285 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.